obesity research is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-26. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Despite its official isolation, however, the government in Mmabatho managed to set up a trade mission in Tel Aviv, Israel, and conducted some business with neighbouring Botswana in an effort to sway attitudes; furthermore, Botswana agreed on "informal arrangements" short of official recognition in order to facilitate cross-border travel. Bophuthatswana maintained an unofficial embassy in Israel during the 1980s, located next to the British embassy in Tel Aviv. The Israeli Foreign Ministry objected to the embassy's presence, as Israel did not recognize Bophuthatswana as a country. The Bantustan's president, Lucas Mangope, was nevertheless able to meet with prominent figures such as Moshe Dayan during visits to Israel. In the 1982 elections, the Democratic Party won all 72 elected seats. It also won a large majority in the 1987 elections.
At one week post-procedure, the patients resumed using the external vacuum tissue-expander for 10 hours daily, until the next fat grafting session; 2–5 outpatient procedures, 6–16 weeks apart, were required until the plastic surgeon and the patient were satisfied with the volume, form, and feel of the reconstructed breasts. The follow-up mammogram and MRI examinations found neither defects (necrosis) nor abnormalities (neoplasms). At six months post-procedure, the reconstructed breasts had a natural form, look, and feel, and the stable breast-volumes ranged 300–600 ml per breast. The post-procedure mammographies indicated normal, fatty breasts with well-vascularized fat, and few, scattered, benign oil cysts. The occurred complications included pneumothorax and transient cysts.
=== Vaso-occlusive crisis === Most people with sickle cell disease have intensely painful episodes called vaso-occlusive crises (VOC). However, the frequency, severity, and duration of these crises vary tremendously. In a VOC, the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries to the tissues, inflammation, and pain. Recurrent episodes may cause irreversible organ damage. The most common and obvious symptom of a VOC is pain, which may be felt anywhere in the body but most commonly in the limbs and back. The degree of pain varies from mild to severe. Home treatment options include bed rest and hydration, and pain control using over-the-counter medication such as paracetamol or ibuprofen. More severe cases may require prescription opioids such as codeine or morphine for pain control. In 2019, crizanlizumab, a monoclonal antibody targeting P-selectin, was approved in the United States to reduce the frequency of vaso-occlusive crisis in those 16 years and older. It had also been approved in the UK and the European Union. In both cases, authorisation was subsequently withdrawn because of poor evidence of its effectiveness.
=== Sneath's index === Sneath's index takes into account 134 categories of activity and structure. Dissimilarity index D is a percentage value of the sum of all properties not shared between two replaced amino acids. It is percentage value expressed by
Sources: en.wikipedia.org
The International History Review. 30 (4): 709–740. doi:10.1080/07075332.2008.10416646. ISSN 1949-6540. JSTOR 40213728. S2CID 153677447. Panzac, Daniel (1995). Histoire économique et sociale de l'Empire ottoman et de la Turquie (1326-1960). Peeters Publishers. ISBN 90-6831-799-7. Pappé, Ilan (2006). The Ethnic Cleansing of Palestine. Oneworld. ISBN 978-1-85168-555-4. Reilly, James A. (2016). The Ottoman Cities of Lebanon: Historical Legacy and Identity in the Modern Middle East. London: I. B. Tauris. ISBN 978-1-78672-036-8. Salibi, Kamal S. (January 1961). "The Buḥturids of the Garb. Mediaeval Lords of Beirut and of Southern Lebanon". Arabica. 8 (1): 74–97. doi:10.1163/157005861X00043. JSTOR 4054971. Salibi, K. (1965). "Fakhr al-Dīn". In Lewis, B.; Pellat, Ch. & Schacht, J. (eds.). The Encyclopaedia of Islam, Second Edition. Volume II: C–G. Leiden: E. J. Brill. pp. 749–751. OCLC 495469475. Salibi, K. (February 1968). "The muqaddams of Bšarrī: Maronite chieftains of the Northern Lebanon 1382–1621". Arabica. 15 (1): 63–86. doi:10.1163/157005868X00280. ISSN 0570-5398. JSTOR 4056124. Salibi, K. (2005). A House of Many Mansions: The History of Lebanon Reconsidered. London: I.B. Tauris. ISBN 978-1-86064-912-7. Salibi, Kamal Suleiman (2005b). The Druze: Realities & Perceptions. University of Michigan Press. ISBN 978-1-904850-06-9. Schilcher, L. Schatkowski (1981). "The Hauran Conflicts of the 1860s: A Chapter in the Rural History of Modern Syria". International Journal of Middle East Studies. 13 (2): 159–179. doi:10.1017/S0020743800055276. JSTOR 162818. S2CID 162263141.
== Advisory committees == Concerns have been raised about FDA advisory committees, including conflicts of interest and pharmaceutical industry ties among members of its committees, divergence of agency decisions from advisory committee recommendations, including the controversial decision to approve the Alzheimer's drug aducanumab, and industry-funded support of individuals and organizations submitting public comments.
Polystyrene (PS) is used for producing disposable plastic cutlery and dinnerware, CD "jewel" cases, smoke detector housings, license plate frames, plastic model assembly kits, and many other objects where a rigid, economical plastic is desired. Production methods include thermoforming (vacuum forming) and injection molding. Polystyrene Petri dishes and other laboratory containers such as test tubes and microplates play an important role in biomedical research and science. For these uses, articles are almost always made by injection molding, and often sterilized post-molding, either by irradiation or by treatment with ethylene oxide. Post-mold surface modification, usually with oxygen-rich plasmas, is often done to introduce polar groups. Much of modern biomedical research relies on the use of such products; they, therefore, play a critical role in pharmaceutical research. Thin sheets of polystyrene are used in polystyrene film capacitors as it forms a very stable dielectric, but has largely fallen out of use in favor of polyester.
=== Codeine === Codeine is a prodrug which is converted to morphine and acts on μ-opiate receptors. It is converted to morphine by metabolism of CYP2D6 enzymes. Individuals who have lower CYP2D6 activity may not metabolize codeine at all, and will not experience its analgesic effects. Conversely, individuals with rapid or ultra-rapid CYP2D6 activity may metabolize the drug too quickly and experience dose-related side effects such as sedation and fatal respiratory depression.
Майкл Вайс, Хасан Хасан. Исламское государство: Армия террора. — Альпина Паблишер, 2015-11-03. — 346 с. — ISBN 978-5-9614-4068-3. Даша Никольсон. Иностранные боевики-террористы с Северного Кавказа: понимание влияния Исламского государства в этом регионе // Connections: The Quarterly Journal. — 2017. — Т. 16, вып. 4 Манойло А.В. «Русская весна» в Сирии // Мировая политика. — 2015–04. — Т. 4, вып. 4. — С. 1–26. — ISSN 2409-8671 | doi:10.7256/2409-8671.2015.4.17318
Sources: en.wikipedia.org
== Society and culture == Addiction carries substantial social and economic consequences, is among the more heavily stigmatized health conditions, and has been interpreted through political and anthropological frameworks as well as medical ones.
Examples of potent CYP1A2 inhibitors include ethinylestradiol (found in hormonal birth control), fluoroquinolones (e.g., ciprofloxacin), fluvoxamine, and St. John's wort, while potent CYP1A2 inducers include phenytoin, rifampin, ritonavir, and tobacco. A study found that ritonavir, a strong CYP3A4 and CYP2D6 inhibitor and moderate CYP1A2 inducer, increased trazodone peak levels by 1.4-fold, trazodone area-under-the-curve levels by 2.4-fold, and decreased trazodone clearance by 50%. This was associated with adverse effects such as nausea, hypotension, and syncope. Another study found that the strong CYP3A4 inducer carbamazepine reduced concentrations of trazodone by 60 to 74%. The strong CYP2D6 inhibitor thioridazine has been reported to increase trazodone levels by 1.4-fold and concentrations of mCPP by 1.5-fold. Fluoxetine, a strong inhibitor of CYP2D6 and a weak or moderate inhibitor of CYP3A4, has been reported to increase levels of trazodone by 1.3- to 1.7-fold and of mCPP by 3.0- to 3.4-fold. Conversely, CYP2D6 genotype has not been found to predict trazodone or mCPP concentrations with trazodone therapy, although CYP2D6 genotype did correlate with side effects like dizziness and prolonged corrected QT interval. Smokers have lower levels of trazodone and higher ratios of mCPP to trazodone. Trazodone levels were 30% lower in smokers and mCPP to trazodone ratio was 1.3-fold higher in smokers, whereas mCPP concentrations were not different between smokers and non-smokers. Smoking is known to induce CYP1A2, and this may be involved in these findings.
==== Other ==== Treatment of breast cancer in women, although they are now rarely used for this purpose due to their marked virilizing side effects. In low doses as a component of hormone therapy for postmenopausal and transgender women, for instance to increase energy, well-being, libido, and quality of life, as well as to reduce hot flashes. Testosterone is usually used for this purpose, although methyltestosterone is also used. Male hormonal contraception; currently experimental, but potential for use as effective, safe, reliable, and reversible male contraceptives. Assistant in the treatment of Raynaud's Phenomenon and peripheral acrocyanosis. Testosterone and other anabolics tend to be potent vasodilators, which can significantly improve bloodflow in individuals prone to vasoconstriction.
HVEC's entry into high-energy research accelerators began in 1949 with its 4 MV Cosmotron particle injector. By 1951, HVEC had begun producing its single-ended CN series that became the first mass-produced research accelerators. The CN design was based on a vertical accelerator at MIT designed by John Trump. It employed resistor grading in both column and tube structure, field-shaping column hoops, and high-pressure insulating gas mixtures of nitrogen and carbon dioxide. Operating in a single stage at terminal voltages up to 6.5 megavolts, the 26 CN models manufactured by HVEC reliable platforms for light-ion nuclear physics experiments. However, fundamental physics questions, particularly the structure of heavier nuclei, demanded higher particle energies than a single-stage Van de Graaff accelerator could reach.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.